Northland Capital partners view on Evgen Pharma PLC: Evgen is positioning itself to become the world’s unique provider of sulforaphane and sulforaphane-like pharmaceuticals. The group is already a first-mover in the area, having the only sulforaphane-based pharmaceutical product, SFX-01, in clinical development. Currently, SFX-01 is Phase 2-ready for two indications, and the treatment has the potential to target several further indications. Today’s agreement gives the group access to a range of novel sulforaphane analogues, under a worldwide exclusive agreement. This agreement provides a pipeline of future potential sulforaphane-like treatments and effectively locks down the sulforaphane landscape, substantially increasing barriers to entry for potential competitors.
| Evgen expands its pipeline with novel compounds |
| n Evgen has acquired exclusive worldwide licensing rights to a wide range of novel compounds from the Spanish National Research Council (CSIC) and the University of Seville, Spain.
n This in-licensing agreement further bolsters the intellectual property position of the Company with rights to more than 60 new chemical entities based on the core structure of sulforaphane, the active ingredient in the company’s lead product SFX-01. n Evgen will use its Sulforadex® platform to synthesise and stabilise the newly acquired compounds with a view to taking the most promising into clinical development. n Under the terms of the worldwide licensing agreement, Evgen Pharma will pay a modest upfront payment and one-off milestone payments as the first compound progresses through clinical development. Royalties on future sales of any marketed products will not exceed 1% of net sales. n Patent protection for the newly in-licensed compounds is pending in Europe, United States, China, Japan, Australia, Canada and is granted in their national home territory of Spain. n The new compounds will complement Evgen Pharma’s SFX-01, a synthetic and stabilised version of sulforaphane, a naturally occurring molecule with established anti-cancer and neuroprotectant properties. Early next year, SFX-01 is expected to enter Phase II trials in subarachnoid haemorrhage and, a few months later, in metastatic breast cancer. |
